Anti-GPR18 (C-Term)

GPR18 is a G protein-coupled receptor (GPCR) that is expressed in lymphoid tissues, lung, brain, testis, and ovaries. It is coupled to the Galphai/o and Galphaq/11 transduction pathways and is activated by the polyunsaturated fatty acid metabolite resolvin D2 (Cay-10007279) and the endocannabinoid arachidonoyl glycine (NAGly, Cay-90051). Resolvin D2-induced activation of GPR18 reduces inflammatory pain induced by formalin, carrageenan, and complete Freund's adjuvant (CFA) in rats and reduces production of pro-inflammatory cytokines in mouse models of cecal ligation and puncture-induced sepsis, ocular infections, and ischemic injury. NAGly-induced activation of GPR18 lowers intraocular pressure (IOP) in mice in a fatty acid amide hydrolase-dependent manner. GPR18 is also overexpressed and constitutively active in patient-derived metastatic melanoma tumor samples. Cayman's GPR18 (C-Term) Polyclonal Antibody can be used for ELISA and immunohistochemistry (IHC) applications. The antibody recognizes the C-terminal region of GPR18 from human samples.Synonyms: N-Arachidonyl Glycine Receptor, GPCRW, G Protein-Coupled Receptor 18, NAGly Receptor. Immunogen: Synthetic peptide from the C-terminal region of human GPR18. Formulation: (Request formulation change), 500 µl of Peptide affinity-purified antibody. Storage Buffer: PBS, pH 7.2, with 50% glycerol and 0.02% sodium azide. Host: Rabbit. Applications: ELISA and IHC. UniProt Accession #: Q14330.